

****Published July 2012****

MarketVIEW: *Candida* vaccines (CAT: VAMV037)

Product Name	:	MarketVIEW: <i>Candida</i> vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + forecast model
Therapeutic Area	:	Novel vaccines
Publication date	:	July 2012
Catalogue No	:	VAMV037

Background

Candida yeasts cause Candidiasis which is a fungal infection commonly found in humans. Infections can occur in the female Genital area “vulvovaginal candidiasis” of which nearly 75% of all adult women have had one “yeast infection” in their lifetime. Some women experience recurrent episodes (RVVC) which can cause considerable inconvenience and distress. Invasive Candidiasis, is a life threatening infection which mainly affects individuals with serious underlying co-morbidities. Infections usually occur in the hospital intensive care unit (ICU) where it is the fourth most common bloodstream infection (CDC Figures).

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of *Candida* vaccines across major Western markets until 2030. The model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates for both Recurrent Vulvovaginal Candidiasis (RVVC) and invasive Candidiasis (in the ICU setting) indications. For RVVC indication 3 prevalence scenarios (LO/MID/HI) are included. The product also includes an up-to-date review of latest competitor activity in the field and *Candida* epidemiology.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to two major Candida disease indications that could be addressed by a putative vaccine approach (RVVC and ICU). Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of nosocomial pathogens has also been utilised.

PRODUCT CONTENTS:

Published July 2012 (CAT No: VAMV037)

****This product is composed of a model and summary presentation

Executive Summary

RVVC TX vaccine: available market (\$000s) to 2030, realistic RVVC prevalence

RVVC TX vaccine: available market (\$000s) to 2030 by conservative, realistic and optimistic RVVC prevalence

RVVC TX vaccine: available market (000s doses) to 2030

Candida ICU PX vaccine: available market (\$000s) to 2030

Candida ICU PX vaccine: available market (000s doses) to 2030

The role of Candida vaccines

Candida ICU PX vaccine: target product profile

RVVC TX vaccine: target product profile

Candida ICU PX vaccine: model assumptions

RVVC TX vaccine: model assumptions

Key commercial model assumptions

Pricing

Competitor landscape: overview

Pevion (PEV7)

NovaDigm Therapeutics (NDV-3)

Vulvovaginal candidiasis: overview

Vulvovaginal candidiasis: surveillance

Vulvovaginal candidiasis: regional data

Vulvovaginal candidiasis: primary care consultations

Vulvovaginal candidiasis: drug utilization

Vulvovaginal candidiasis: drug utilization

Vulvovaginal candidiasis: population based studies

Vulvovaginal candidiasis: incidence/prevalence summary

Invasive candidiasis: overview

Invasive candidiasis: national surveillance data

Invasive candidiasis: estimating ICU admissions

Bibliography

Disclaimer

About **VacZine Analytics**

PAGES: 50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title
Scenarios
Charts value (RVVC)
Charts value (ICU)
Charts volume (RVVC and ICU)
Value summary (ICU)
Volume summary (ICU)
Value summary (RVVC)
Volume summary (RVVC)
Model inputs (RVVC)
ICU patients =>
US (ICU)
UK (ICU)
CANADA (ICU)
GERMANY (ICU)
SPAIN (ICU)
FRANCE (ICU)
ITALY (ICU)
EU other (ICU)
AUSTRALIA (ICU)
JAPAN (ICU)
RVVC patients =>
LO/BASE/HI prevalence scenarios
US (RVVC)
UK (RVVC)
CANADA (RVVC)
GERMANY (RVVC)
SPAIN (RVVC)
FRANCE (RVVC)
ITALY (RVVC)
EU other (RVVC)
AUSTRALIA (RVVC)
JAPAN (RVVC)
Source material →
ICU database
RVVC database
UK RVVC epi
US ICU epi
Back page

Worksheets = >60 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$7995.00/ GBP £5150.00[#] (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. Kuebrich CT. N Engl J Med. 2004 Dec 9;351(24):2554-6; author reply 2554-6 Chronic vulvovaginal candidiasis.
2. Hassan I et al. Excess mortality, length of stay and cost attributable to candidaemia. J Infect. 2009 Nov;59(5):360-5.
3. Pevion Press Release. Pevion's therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity, while epidemiological survey confirms excellent market potential. October 11th, 2011
4. Pevion's therapeutic Candida vaccine generates functional B cell memory in all vaccinees. January 17, 2012
5. NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine. May 7, 2012 .
6. Senterre JM et al. [Vulvovaginal candidiasis: prevalence of different Candida species in the Liege region]. Rev Med Liege. 2005 Nov;60(11):882-4.
7. Foxman B The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health. 1990 Mar;80(3):329-31.
8. Sobel JD et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004 Aug 26;351(9):876-83.
9. Pevion Biotech. PEV7 Active immunotherapy against RVVC. May 2012. Available at: pevion.com. Accessed: July 2012.
10. Pevion Biotech. RVVC Recurrent Vulvovaginal Candidiasis. June 2012. Available at: pevion.com. Accessed: July 2012.
11. Toumi M. Survey on health-related quality of life and treatment patterns among women with recurrent vulvovaginal candidiasis (RVVC).Creativ-Ceutical (France), 2012. Manuscript in preparation
12. Foxman B et al. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis. 2000 Apr;27(4):230-5.
13. Mårdh PA et al. Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: I. Analyses of a unique database. Infect Dis Obstet Gynecol. 2004 Jun;12(2):91-7.
14. Paulitsch A et al. A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses. 2006 Nov;49(6):471-5.
15. Corsello S et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol. 2003 Sep 10;110(1):66-72.
16. Research & Surveillance Centre. Weekly Returns Service Annual Report 2010. Available at: www.rcgp.org.uk. Accessed: July 2012.
17. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. National Center for Health Statistics. Vital Health Stat 13(169). 2011
18. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1995. National Center for Health Statistics. Vital Health Stat 13(129). 1997.
19. Foxman B et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European Countries and the US: Results from an Internet Panel Survey. 2012. Submitted
20. Pevion Biotech. Annual report, 2011 June 2012. April 2012.
21. Vazquez JA et al Invasive fungal infections in the intensive care unit. Semin Respir Crit Care Med. 2010 Feb;31(1):79-86.
22. Leroy O et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009 May;37(5):1612-8.
23. Schelenz S. Management of candidiasis in the intensive care unit. J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i31-4.
24. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide study. Clin Infect Dis 2004, 39:309-317.
25. Ostrosky-Zeichner L et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):271-6.
26. Hermsen ED et al. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care. 2011 Aug 9;15(4):R198.
27. Ostrosky-Zeichner L et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011 Jan;54(1):46-51.
28. Wenzel RP et al. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis. 2005 Sep 15;41 Suppl 6:S389-93.
29. Health Protection Agency. Health Protection Report Vol 5 No. 37 - 16 September 2011.
30. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD. Available at: <http://hcupnet.ahrq.gov/>. Accessed: July 2012.
31. Vincent JL et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2;302(21):2323-9.
32. Kett DH et al. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011 Apr;39(4):665-70.

33. Wunsch H et al. Variation in critical care services across North America and Western Europe. *Crit Care Med*. 2008 Oct;36(10):2787-93, e1-9.
34. Wunsch H et al. Comparison of medical admissions to intensive care units in the United States and United Kingdom. *Am J Respir Crit Care Med*. 2011 Jun 15;183(12):1666-73.
35. Harrison DA et al. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. *Crit Care*. 2006;10(2):R42.
36. Adult Critical Care data in England - April 2010 to March 2011: Experimental Statistics. Available at: <http://www.hesonline.nhs.uk>. Accessed: July 2012
37. Abt Associates. Future Needs in Pulmonary and Critical Care Medicine. November 13, 1998. Available at: www.abtassociates.com/reports/chest2.pdf. Accessed: July 2012.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009